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In a recent article, Lee et al. reported about a study on the relation between magnetic resonance spectroscopy (MRS) and serum biomarkers during acute and chronic stages of a stroke-like episode (SLE) in 13 patients carrying the mtDNA variant m.3243A>G. The study is interesting but has a number of shortcomings.
The main disadvantage of the study is that heteroplasmy rates of the m.3243A>G variant were not considered as determinants of the correlation between MRS parameters (NNA/Cr, Chol/Cre, NAA/ Chol, lactate) and serum lactate/pyruvate. Since there may be a strong genotype/phenotype correlation, any correlation between serum/ MRS biomarkers can be reliably assessed only when the mutation load is known. Also, the influence of the variability of heteroplasmy rates between tissues on MRS/serum biomarkers correlations should be considered. However, heteroplasmy rates of blood lymphocytes may not correlate with those of brain tissue and heteroplasmy rates may not be the only determinant of the phenotype.
Secondly, it is unclear at which point of a SLE serum/MRS biomarkers were determined. Since stroke-like lesions (SLLs), the morphological equivalent of a SLE, undergo rapid changes over time, the exact interval between onset of a SLE and the investigation should be known. Since MRS findings strongly depend on the stage and volume of a SLL, it should be mentioned if the investigations were repeated at a second or third time point, and if differences between different time points were found. Since no follow-up investigations were carried out and no information about the development of the serum/MRS biomarker relationship over time is available, we do not agree with the statement that serum/MRS biomarkers relationships are useful for monitoring the progression of MELAS [1] .
Severity and outcome of SLLs may strongly depend on whether affected patients received nitric-oxide (NO) precursors or not [2] . Those receiving NO-precursors may have a milder course and a more favourable outcome than those without receiving them. This is why the number of patients receiving NO-precursors should be provided?
Lactate concentrations may strongly depend on whether there was previous seizure activity or not [3] . Since epilepsy is a frequent feature of MELAS and strongly influences the outcome and prognosis [4] , we should be informed how many of the patients experienced a seizure prior to the examination. Since seizure frequency strongly depends on the quality of seizure control, we should also know which antiepileptic drugs the patients were regularly taking.
Since serum lactate derives from the skeletal muscle and cerebral lactate from the brain, it should be mentioned how many of the included patients had mitochondrial myopathy. It should be also mentioned how many had elevated serum lactate but normal CSF lactate and vice versa.
In summary, we do not agree with the conclusions of the study as long as the influence of heteroplasmy rates, previous seizures, antiepileptic treatment, and disease stage on biomarker correlations
